Vascular endothelial growth factor a promotes vaccinia virus entry into host cells via activation of the Akt pathway

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2781-2790

  Hiley, Crispin T ^a   Chard, Louisa S ^a   Gangeswaran, Rathi ^a   Tysome, James R ^a   Briat, Arnaud ^a   Lemoine, Nicholas R ^a,b   Wanga, Yaohe ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; PROTEIN KINASE B; SMALL INTERFERING RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRAL TROPISM; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; ANOXIA; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; EPITHELIAL CELLS; GENES, REPORTER; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; RESPIRATORY MUCOSA; RNA INTERFERENCE; RNA, SMALL INTERFERING; VACCINIA; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL TROPISM; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84874751445     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00854-12     Document Type: Article

References (49)

1. Fenner F. 1988. Smallpox and its eradication (History of international public health, no. 6). World Health Organization, Geneva, Switzerland.
2. Kanesa-thasan, N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE. 2000. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinianonimmune and vaccinia-immune humans. Vaccine 19:483-491.
3. Kirn DH, Thorne SH. 2009. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9:64-71.
4. + T-cell responses. Infect. Immun. 78:145-153.
5. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Munoz M, Harshman K, Esteban M. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77:6493-6506.
6. Wong HH, Lemoine NR, Wang Y. 2010. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2:78-106.
7. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQM, Nieva J, Hwang T-H, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je J-E, Lee Y-S, Parato K, Diallo J-S, Fenster A, Daneshmand M, Bell JC, Kirn DH. 2011. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477:99-102.
8. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. 2008. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9:533-542.
9. Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, Wang E, Szalay AA, Marincola FM. 2011. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 11:451. doi:10.1186/1471-2407-11-451.
10. Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J, Wang P, Yang S, Dong Z, Wang S, Deng L, Francis J, Timiryasova T, Fodor I, Lemoine NR, Wang Y. 2009. Lister strain of vaccinia virus armed with endostatinangiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 16:1223-1233.
11. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. 2003. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9:555-561.
12. Shen B, Bauzon M, Hermiston T. 2006. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther. 13:986-990.
13. Shen B, Hermiston T. 2005. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 12:902-910.
14. Hiley CT, Yuan M, Lemoine NR, Wang Y. 2010. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 17:281-287.
15. Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L, Levitsky H, Wu TC. 2007. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther. 14:20-29.
16. Warren JC, Rutkowski A, Cassimeris L. 2006. Infection with replicationdeficient adenovirus induces changes in the dynamic instability of host cell microtubules. Mol. Biol. Cell 17:3557-3568.
17. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
18. Vanderplasschen A, Smith G. 1997. A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J. Virol. 71:4032-4041.
19. Wang Y, Gangeswaran R, Zhao X, Wang P, Tysome J, Bhakta V, Yuan M, Chikkanna-Gowda CP, Jiang G, Gao D, Cao F, Francis J, Yu J, Liu K, Yang H, Zhang Y, Zang W, Chelala C, Dong Z, Lemoine N. 2009. CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J. Clin. Invest. 119:1604-1615.
20. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. 2010. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102:1555-1577.
21. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676.
22. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. 2007. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691-703.
23. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, Sessa WC. 2000. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/ threonine kinase Akt. Circ. Res. 86:892-896.
24. Rousseau S, Houle F, Landry J, Huot J. 1997. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15:2169-2177.
25. Frischknecht F, Moreau V, Rottger S, Gonfloni S, Reckmann I, Superti-Furga G, Way M. 1999. Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature 401:926-929.
26. Calleja V, Laguerre M, Parker PJ, Larijani B. 2009. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 7:e1000017. doi:10.1371/journal .pbio.1000017.g002.
27. Ahlbrecht K, Schmitz J, Seay U, Schwarz C, Mittnacht-Kraus R, Gaumann A, Haberberger RV, Herold S, Breier G, Grimminger F, Seeger W, Voswinckel R. 2008. Spatiotemporal expression of flk-1 in pulmonary epithelial cells during lung development. Am. J. Respir. Cell Mol. Biol. 39:163-170.
28. Le A, Zielinski R, He C, Crow MT, Biswal S, Tuder RM, Becker PM. 2009. Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema. Am. J. Respir. Crit. Care Med. 180:396-406.
29. Lee CG, Yoon HJ, Zhu Z, Link H, Wang Z, Gwaltney JM, Jr, Landry M, Elias JA. 2000. Respiratory syncytial virus stimulation of vascular endothelial cell growth factor/vascular permeability factor. Am. J. Respir. Cell Mol. Biol. 23:662-669.
30. Vermeer PD, McHugh J, Rokhlina T, Vermeer DW, Zabner J, Welsh MJ. 2007. Vaccinia virus entry, exit, and interaction with differentiated human airway epithelia. J. Virol. 81:9891-9899. 31. Newman PJ. 1997. The biology of PECAM-1. J. Clin. Invest. 99:3-8.
31. Newman PJ. 1997. The biology of PECAM-1. J. Clin. Invest. 99:3-8.
32. Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320:531-535.
33. Mercer J, Knabel S, Schmidt FI, Crouse J, Burkard C, Helenius A. 2009. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc. Natl. Acad. Sci. U. S. A. 107:9346-9351.
34. Moss B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54.
35. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA. 2004. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 22:313-320.
36. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC. 2012. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20:749-758.
37. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. 2007. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117:3350-3358.
38. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. 2010. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog. 6:e1001099. doi:10.1371 /journal.ppat.1001099.
39. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. 2010. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 16:662-664.
40. Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA. 1999. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. U. S. A. 96:3071-3076.
41. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ, McFadden G. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrinrepeat host range factor. Proc. Natl. Acad. Sci. U. S. A. 103:4640-4645.
42. Ghez D, Lepelletier Y, Lambert S, Fourneau J-M, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O. 2006. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 80:6844-6854.
43. Whitbeck JC, Foo C-H, Ponce de Leon M, Eisenberg RJ, Cohen GH. 2009. Vaccinia virus exhibits cell-type-dependent entry characteristics. Virology 385:383-391.
44. Izmailyan R, Hsao JC, Chung CS, Chen CH, Hsu PW, Liao CL, Chang W. 2012. Integrin beta1 mediates vaccinia virus entry through activation of PI3K/Akt signaling. J. Virol. 86:6677-6687.
45. Oommen S, Gupta SK, Vlahakis NE. 2011. Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site. J. Biol. Chem. 286:1083-1092.
46. Somanath PR, Ciocea A, Byzova TV. 2009. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem. Biophys. 53:53-64.
47. Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR, Bartlett DL. 2005. Targeting vaccinia to solid tumors with local hyperthermia. Hum. Gene Ther. 16:435-444.
48. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
49. Harrison SC, Alberts B, Ehrenfeld E, Enquist L, Fineberg H, McKnight SL, Moss B, O'Donnell M, Ploegh H, Schmid SL, Walter KP, Theriot J. 2004. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:11178-11192.